 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||
| about advanced cancer therapeutics | ||||||
founders & management Gilles Tapolsky, Ph.D. Prior to joining ACT, Dr. Tapolsky served as Vice President, Product Development at Tapestry Pharmaceuticals of Boulder, Colorado. In this position, he led the development of new anti-cancer agents, designing and implementing pre-clinical studies of multiple compounds. He was also a member of the clinical development group and supported all clinical studies. Previously, Dr. Tapolsky was Vice President, Research & Development at FeRx Incorporated where he was responsible for building that company’s drug discovery efforts and evaluating business development opportunities. He was awarded several NIH grants to further explore the use of the MTC technology for the targeted delivery of anti-cancer agents. Earlier in his career, Dr. Tapolsky was Director, Product Development at ViroTex where he conceived and developed the BEMA® and MCA® technologies. Further development of these technologies resulted in the successful development of several products, as well as the implementation of a number of corporate collaborations. Before joining ViroTex, Dr. Tapolsky held several senior Research and Development positions at Flamel Technologies, in Lyon, France, that he helped co-found. He started his career as a research scientist in the materials science department of Rhone-Poulenc Rhorer where he contributed to the design, synthesis and characterization of novel products. Dr. Tapolsky holds a Ph.D. in Chemistry for the University of Paris as well as an MBA from Rice University in Houston. |
|
|||||
 |
 |
|||||
